Skip to main content
Avivagen Inc. logo

Avivagen Inc. — Investor Relations & Filings

Ticker · VIV ISIN · CA05382F2026 TSXV Manufacturing
Open in API
Filings indexed 552 across all filing types
Latest filing 2024-04-24 Regulatory Filings
Country CA Canada
Listing TSXV VIV

About Avivagen Inc.

http://www.avivagen.com

Avivagen Inc. was a life sciences corporation focused on developing and commercializing natural health products for livestock, companion animals, and humans. The company specialized in feed additives designed to support immune function and promote growth in animals, emphasizing science-based validation through clinical trials. On April 23, 2024, Avivagen Inc. filed a voluntary assignment in bankruptcy, and a trustee was appointed to manage the proceedings.

Recent filings

Filing Released Lang Actions
News release - English.pdf
Regulatory Filings Classification · 95% confidence The document is a press release announcing Avivagen Inc.'s voluntary assignment into bankruptcy under the Bankruptcy and Insolvency Act (BIA). It discusses the company's failure to file audited annual financial statements and management's discussion and analysis for the year ended October 31, 2023, and mentions the halt and anticipated permanent halt of trading on the TSXV pending delisting. The document is not a financial report itself but an announcement of a significant corporate event (bankruptcy filing and related trading halt). It does not contain financial statements or detailed financial data but rather informs stakeholders about the bankruptcy and related procedural matters. Therefore, it fits best into the category of Regulatory Filings (RNS), which covers general regulatory announcements and compliance-related disclosures that do not fit other specific categories.
2024-04-24 English
News release - English.pdf
Regulatory Filings Classification · 95% confidence The document is a press release announcing a new 500kg order for Avivagen's OxC-beta™ product. It contains no financial statements, no regulatory form references, no management discussion of financial results, and no mention of shareholder meetings or voting results. The content focuses on a business update regarding product sales and forward-looking statements about the company's prospects. It is not a financial report, audit, earnings release, or regulatory filing. It is a typical corporate news announcement about a sales order, which fits best under the category of a general regulatory announcement or miscellaneous filing that does not fit other categories. Therefore, the most appropriate classification is Regulatory Filings (RNS). The document length is about 5,044 characters, which is short and consistent with a news release rather than a detailed report.
2023-10-17 English
News release - English.pdf
Interim / Quarterly Report Classification · 95% confidence The document is titled "Management's Discussion and Analysis (MD&A)" and dated September 28, 2023. It discusses the financial condition and results of operations for the three-month period ended July 31, 2023, including detailed financial data such as revenue, expenses, net loss, cash flows, and quarterly financial information. The document references unaudited interim consolidated financial statements prepared under IFRS and IAS 34, which pertains to interim financial reporting. The content is comprehensive and includes substantive financial data and analysis for a period shorter than a full fiscal year (quarterly). This matches the definition of an Interim / Quarterly Report (IR). The document is about 15,000 characters long, indicating it is a full report rather than a brief announcement or certification. Therefore, the appropriate classification is IR with high confidence. Q1 2024
2023-09-29 English
52-109FV2 - Certification of interim filings - CEO (E).pdf
Regulatory Filings Classification · 95% confidence The document is a Form 52-109FV2 Certification of Interim Filings Venture Issuer Basic Certificate by the CEO of Avivagen Inc. It certifies the review and fair presentation of the interim financial report and interim MD&A for the period ended July 31, 2023. The document is primarily an officer certification letter and does not contain actual financial statements or substantive financial data. It references the interim filings but does not include them. According to the Certification Rule, such certification documents should be classified as Regulatory Filings (RNS) rather than as the interim report itself (IR). The document length is short (2990 characters), consistent with a certification letter rather than a full report.
2023-09-29 English
52-109FV2 - Certification of interim filings - CFO (E).pdf
Regulatory Filings Classification · 95% confidence The document is a Form 52-109FV2 Certification of Interim Filings Venture Issuer Basic Certificate by the CFO of Avivagen Inc. It certifies the review and fair presentation of the interim financial report and interim MD&A for the period ended July 31, 2023. The document is primarily an officer certification letter and does not contain actual financial statements or substantive financial data. It references the interim filings but does not include them. According to the Certification Rule, such certification documents should be classified as Regulatory Filings (RNS) rather than as the interim report itself (IR). The document length is under 5,000 characters and is a certification, not the report itself.
2023-09-29 English
Interim MD&A - English.pdf
Interim / Quarterly Report Classification · 95% confidence The document is titled 'Summary Financial Information and Management's Discussion and Analysis of Financial Condition and Results of Operations' (MD&A) for the three- and nine-month periods ended July 31, 2023. It includes management's responsibility statements, certifications by CEO and CFO under National Instrument 52-109, and detailed discussion of financial condition, risks, forward-looking statements, and operational overview. The document references unaudited interim financial statements and discusses quarterly financial results and outlook. The length is substantial (15,000 characters), indicating it is a full report rather than a brief announcement or certification. The content matches the characteristics of an Interim / Quarterly Report (IR), which includes substantive financial data and management analysis for a period shorter than a full fiscal year. Therefore, the document should be classified as an Interim / Quarterly Report (IR). 9M 2023
2023-09-29 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.